{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Choi E"],"funding":["NCI NIH HHS","National Institutes of Health"],"pagination":["618-625"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9002287"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["114(4)"],"pubmed_abstract":["<h4>Background</h4>Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC), but little is known about the survival impact of SPLC diagnosis.<h4>Methods</h4>We analyzed data from 138 969 patients in the Surveillance, Epidemiology, and End Results (SEER), who were surgically treated for initial primary lung cancer (IPLC) in 1988-2013. Each patient was followed from the date of IPLC diagnosis to SPLC diagnosis (for those with SPLC) and last vital status through 2016. We performed multivariable Cox regression to evaluate the association between overall survival and SPLC diagnosis as a time-varying predictor. To investigate potential effect modification, we tested interaction between SPLC and IPLC stage. Using data from the Multiethnic Cohort Study (MEC) (n = 1540"],"journal":["Journal of the National Cancer Institute"],"pubmed_title":["The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer."],"pmcid":["PMC9002287"],"funding_grant_id":["R37 CA226081","1R37CA226081","P30 CA071789"],"pubmed_authors":["Wilkens LR","Neal JW","Luo SJ","Choi E","Su CC","Backhus LM","Aredo JV","Han SS","Cheng I","Wakelee HA","Le Marchand L"],"additional_accession":[]},"is_claimable":false,"name":"The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer.","description":"<h4>Background</h4>Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC), but little is known about the survival impact of SPLC diagnosis.<h4>Methods</h4>We analyzed data from 138 969 patients in the Surveillance, Epidemiology, and End Results (SEER), who were surgically treated for initial primary lung cancer (IPLC) in 1988-2013. Each patient was followed from the date of IPLC diagnosis to SPLC diagnosis (for those with SPLC) and last vital status through 2016. We performed multivariable Cox regression to evaluate the association between overall survival and SPLC diagnosis as a time-varying predictor. To investigate potential effect modification, we tested interaction between SPLC and IPLC stage. Using data from the Multiethnic Cohort Study (MEC) (n = 1540","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-21T17:29:21.532Z","creation":"2025-04-05T16:40:28.867Z"},"accession":"S-EPMC9002287","cross_references":{"pubmed":["34893871"],"doi":["10.1093/jnci/djab224"]}}